Key result
Basal septal hypertrophy marks early LV remodeling in hypertensive heart disease to guide preventive treatment.
Why the study?
Hypertension drives left ventricular remodeling and heart failure, prompting a focus on basal septal hypertrophy as an early imaging biomarker of hypertensive heart disease.
Can imaging of basal septal hypertrophy (BSH) serve as an early biomarker for adaptive left ventricular remodeling in hypertension?
Can imaging of basal septal hypertrophy (BSH) serve as an early biomarker for adaptive left ventricular remodeling in hypertension?
Basal septal hypertrophy may serve as an early imaging biomarker to detect adaptive left ventricular remodeling in hypertensive patients, potentially allowing for earlier intervention to prevent heart failure.
Hypothesis-generating for BSH as remodeling biomarker in hypertension; leaves open prospective trials before clinical adoption.
Hypertension plays a dominant role in the development of left ventricular (LV) remodeling and heart failure, in addition to being the main risk factor for coronary artery disease. In this review, we focus on the focal geometric and functional tissue aspects of the LV septal base, since basal septal hypertrophy (BSH), as the early imaging biomarker of LV remodeling due to hypertensive heart disease, is detected in cross-sectional clinic studies. In addition, the validation of BSH by animal studies using third generation microimaging and relevant clinical observations are also discussed in the report. Finally, an evaluation of both human and animal quantitative imaging studies and the importance of combined cardiac imaging methods and stress-induction in the separation of adaptive and maladaptive phases of the LV remodeling are pointed out. As a result, BSH, as the early imaging biomarker and quantitative follow-up of functional analysis in hypertension, could possibly contribute to early treatment in a timely fashion in the prevention of hypertensive disease progression to heart failure. A variety of stress stimuli in etiopathogenesis and the difficulty of diagnosing pure hemodynamic overload mediated BSH lead to an absence of the certain prevalence of this particular finding in the population.
No takes yet. Share an insight, caveat, or question.
Yalçın et al. (2021) conducted a review in Hypertensive heart disease and left ventricular remodeling. Basal septal hypertrophy (BSH) imaging was evaluated. Basal septal hypertrophy serves as an early imaging biomarker of left ventricular remodeling in hypertensive heart disease, potentially guiding early treatment to prevent heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: